COMMUNIQUÉS West-GlobeNewswire

IN8bio to Present at International Society for Cell & Gene Therapy (ISCT) 2024
24/05/2024
NEW YORK, May 24, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced multiple presentations at the [...]
Cullinan Therapeutics to Participate in Fireside Chat at TD Cowen 5th Annual Oncology Innovation Summit
24/05/2024
CAMBRIDGE, Mass., May 24, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc . (Nasdaq: CGEM), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced that Nadim Ahmed, [...]
Monopar Announces CFO Succession
24/05/2024
WILMETTE, Ill., May 24, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharmaceutical company focused on developing innovative treatments for cancer patients, today announced [...]
BriaCell Doubles Progression-Free-Survival (PFS) and Reports Clinical Benefit Data at ASCO 2024
24/05/2024
83% intracranial objective response rate (iORR) with Bria-IMT™ in heavily pretreated advanced breast cancer patients with CNS metastases Median progression free survival (PFS) of 4.1 months in ADC resistant patients - [...]
Genelux Corporation Announces Pricing of Approximately $27.5 Million Underwritten Offering of Common Stock and Accompanying Warrants
24/05/2024
WESTLAKE VILLAGE, Calif., May 24, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (Genelux) (Nasdaq: GNLX), a late clinical-stage immuno-oncology company, today announced the pricing of an underwritten offering of 6,875, [...]
BridgeBio Pharma to Present Additional Analyses from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the 2024 ISA Meeting
24/05/2024
- BridgeBio to host investor call on Wednesday, May 29, 2024 at 5:30 pm ET, with presentations from Mathew Maurer, M.D. of Columbia University Irving Medical Center, U.S. and Ahmad Masri, M.D., M.S. of Oregon Health [...]
Laguna Treatment Center Unveils New Name and Expanded Mission with Ribbon-Cutting Ceremony
24/05/2024
ALISO VIEJO, Calif., May 24, 2024 (GLOBE NEWSWIRE) -- Laguna Treatment Center, a leading provider of addiction treatment services, celebrated a significant milestone on May 23 with a ribbon-cutting ceremony at its newly [...]
Bio-Path Holdings to Present Data at 2024 European Hematology Association Congress
24/05/2024
Presentation Includes Positive Results from Interim Analysis of Phase 2 Clinical Trial of Prexigebersen in Acute Myeloid Leukemia (AML) HOUSTON, May 24, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a [...]
Minutes of Annual General Meeting 2024
24/05/2024
Oslo, 24 May 2024. The Annual General Meeting in PCI Biotech Holding ASA took place today, 24 May 2024. All the matters on the agenda were approved and the minutes of the Annual General Meeting are attached to this [...]
Enterome Highlights High Complete Response Rate in Clinical Study of EO2463 for Indolent Non-Hodgkin Lymphoma at ASCO 2024
24/05/2024
- Beneficial clinical responses observed with EO2463 monotherapy already at 6 weeks and complete response rate of 78% in patients treated with EO2463 upon addition of lenalidomide ± rituximab - EO2463 rapidly expands [...]
Atrogi Announces Publication on Advancements in Combatting Obesity and Metabolic Complications
24/05/2024
Preclinical data shows precision modulation of beta-2 and beta-3 signaling boosts metabolism and enhances body recomposition STOCKHOLM, Sweden, May 24, 2024 (GLOBE NEWSWIRE) -- Atrogi, a pioneering clinical-stage [...]
Lift BioSciences Announces Abstract Publications at the American Society of Clinical Oncology (ASCO) Annual Meeting
24/05/2024
Lift BioSciences Announces Abstract Publications at the American Society of Clinical Oncology (ASCO) Annual Meeting London, 24 May 2024 – LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly emerging biotech company [...]
Nicox: 2024 Ordinary Shareholder Meeting to be held on June 28th, 2024
24/05/2024
Press Release Nicox: 2024 Ordinary Shareholder Meeting to be held on June 28 th , 2024 May 24, 2024 – release at 7:30 am CET Sophia Antipolis, France Nicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an [...]
Nicox : Assemblée Générale Ordinaire le 28 juin 2024
24/05/2024
Communiqué de presse Nicox : Assemblée Générale Ordinaire le 28 juin 2024 24 mai 2024 – diffusion à 7h30 Sophia Antipolis, France Nicox SA (Euronext Growth Paris : FR0013018124, ALCOX, éligible PEA-PME), société [...]
ONWARD® Medical fait le point sur le premier trimestre 2024 et sur les faits marquants de l’année écoulée
24/05/2024
La revue Nature Medicine a publié les résultats de l’essai clinique pivot Up-LIFT Dépôt auprès de la FDA d’une demande de classification du dispositif ARC-EX ® System basée sur les risques (demande « De Novo ») Levée de [...]
Adlai Nortye Ltd. to Present Encouraging Data of the Combination of AN0025 and Definitive Chemoradiotherapy (dCRT) at ASCO 2024
24/05/2024
SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, May 23, 2024 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company focused on the [...]
3Daughters to Participate in Women’s Health Panel During the 2024 BIO International Convention in San Diego, CA, June 3-6
23/05/2024
MANSFIELD, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- 3Daughters , Inc., a clinical development company fueling evolutionary healthcare for women, announced that Mary Beth Cicero, Co-Founder and CEO, will participate in an [...]
Premier Health Reports 2024 Second Quarter Results
23/05/2024
MONTRÉAL, May 23, 2024 (GLOBE NEWSWIRE) -- Premier Health of America Inc. (TSXV: PHA ) (the “ Corporation ”), a leading Canadian Healthtech company, announces it has filed its Unaudited Quarterly Consolidated Financial [...]
Elicio Therapeutics Announces Preliminary Data from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual Meeting
23/05/2024
ELI-002 7P administered as a monotherapy was well tolerated and able to generate a ~100x mKRAS-specific expanded T cell response relative to baseline levels ELI-002 7P generated an mKRAS-specific T cell response in 100 [...]

Pages